Physician profile
Jarod Masci
NPI 1689836181
$5,386.81
in general payments reported to CMS, 2019-2025
31 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $713 · 2021: $727 · 2022: $751 · 2023: $991 · 2024: $618 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,177.56 | 2019-2025 | Spravato |
| Abbvie INC. | $607.18 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $528.49 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $480.19 | 2020-2024 | Caplyta |
| Orexo US, INC. | $289.53 | 2019-2023 | Zubsolv |
| Indivior INC. | $262.46 | 2019-2023 | Sublocade |
| Neuronetics, INC. | $248.26 | 2019-2021 | |
| Mdd US Operations, LLC | $217.75 | 2019-2020 | |
| Lundbeck LLC | $196.52 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $150.92 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $140.55 | 2019-2023 | Trintellix |
| Alkermes, INC. | $121.89 | 2019-2025 | Vivitrol, Vivitrol |
| Gilead Sciences, INC. | $115.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $101.78 | 2020-2022 | |
| Alfasigma USA, INC. | $91.32 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $84.77 | 2022-2023 | Austedo, Austedo Xr |
| Corium, LLC | $62.54 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $52.48 | 2023 | Wegovy |
| Neos Therapeutics, LP | $49.88 | 2019-2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $49.53 | 2022-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $48.65 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $45.02 | 2020-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $42.75 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $40.72 | 2021-2022 | |
| Uswm, LLC | $34.93 | 2021 | |
| Eisai INC. | $33.93 | 2020-2021 | |
| Adlon Therapeutics L.P. | $30.95 | 2020 | |
| Bausch Health US, LLC | $30.50 | 2019-2020 | |
| Shire North American Group INC | $20.95 | 2019 | |
| Noven Therapeutics, LLC | $17.63 | 2024 | Xelstrym, Secuado |
| Merck Sharp & Dohme LLC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarod Masci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.